Molecule Information

General Information of the Molecule (ID: Mol04189)

• Name: Sponging microRNAs ,Homo sapiens
• Molecule Type: miscRNA

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Temozolomide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Disease Class: Diffuse glioma [ICD-11: 2A00.0] [1]

• Metabolic Type: Glucose metabolism
• Resistant Disease: Diffuse glioma [ICD-11: 2A00.0]
• Resistant Drug: Temozolomide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: TMZ-resistant patients; Homo Sapiens
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Overall survival assay (OS)
• Mechanism Description: Exosomal circ_0072083 promoted TMZ resistance via increasing NANOG via regulating miR-1252-5p-mediated degradation and demethylation in glioma.

Disease Class: Diffuse glioma [ICD-11: 2A00.0] [1]

• Metabolic Type: Glucose metabolism
• Resistant Disease: Diffuse glioma [ICD-11: 2A00.0]
• Resistant Drug: Temozolomide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• In Vitro Model: U87 cells; Brain; Homo sapiens (Human); CVCL_0022
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: IC50 assay
• Mechanism Description: Exosomal circ_0072083 promoted TMZ resistance via increasing NANOG via regulating miR-1252-5p-mediated degradation and demethylation in glioma.

Disease Class: Diffuse glioma [ICD-11: 2A00.0] [1]

• Metabolic Type: Glucose metabolism
• Resistant Disease: Diffuse glioma [ICD-11: 2A00.0]
• Resistant Drug: Temozolomide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: U251 cell xenograft model, U251/TR-sh-NC EXO; Mice
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Tumor volume assay
• Mechanism Description: Exosomal circ_0072083 promoted TMZ resistance via increasing NANOG via regulating miR-1252-5p-mediated degradation and demethylation in glioma.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Disease Class: Diffuse glioma [ICD-11: 2A00.0] [1]

• Metabolic Type: Glucose metabolism
• Sensitive Disease: Diffuse glioma [ICD-11: 2A00.0]
• Sensitive Drug: Temozolomide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• In Vitro Model: U87 cells; Brain; Homo sapiens (Human); CVCL_0022
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: IC50 assay
• Mechanism Description: Exosomal circ_0072083 promoted TMZ resistance via increasing NANOG via regulating miR-1252-5p-mediated degradation and demethylation in glioma.

Disease Class: Diffuse glioma [ICD-11: 2A00.0] [1]

• Metabolic Type: Glucose metabolism
• Sensitive Disease: Diffuse glioma [ICD-11: 2A00.0]
• Sensitive Drug: Temozolomide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: U251 cell xenograft model, U251/TR-sh-circ_0072083 EXO; Mice
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Tumor volume assay
• Mechanism Description: Exosomal circ_0072083 promoted TMZ resistance via increasing NANOG via regulating miR-1252-5p-mediated degradation and demethylation in glioma.

References

• Ref 1: Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. J Exp Clin Cancer Res. 2021 May 11;40(1):164.